china tirzepatide

china tirzepatide chinese monotherapy in patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) Tirzepatide Manufacturers & Suppliers – Lilly plans $200M expansion in

Name: china tirzepatide chinese monotherapy in patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) Tirzepatide Manufacturers & Suppliers – Lilly plans $200M expansion in
Brand: actil.am
SKU: 89006496252
Price: 24.34 USD
Availability: InStock
Rating: 4.0864 (26 reviews)

SKU: 89006496252

4.1

USD24.34 USD60.34

Pay in 4 interest-free payments of $6.08 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

Description

In the secondary endpoint, subjects treated with tirzepatide achieved an overall mean weight loss of 26.6% after 12 weeks of intensive lifestyle intervention followed by 72 weeks of tirzepatide treatment